NovaBridge Biosciences
جودة البيانات: 83%
NBP
Nasdaq
Manufacturing
Chemicals
KWD 2.36
▼
KWD 0.08
(-3.40%)
القيمة السوقية: 277.85 M
السعر
KWD 2.41
القيمة السوقية
277.85 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue declined -53.75% annually over 5 years
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 53.75%
Capital efficient — spends only 1.11% of revenue on capex
النمو
Revenue Growth (5Y)
-53.75%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-20.31%
أعلى من متوسط القطاع (-53.34%)
ROIC-32.33%
Net Margin-7321.04%
Op. Margin-14915.98%
الأمان
Debt / Equity
N/A
Current Ratio14.47
Interest CoverageN/A
التقييم
PE (TTM)
-6.01
أقل من متوسط القطاع (-1.47)
P/B Ratio1.07
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -6.0 | -1.5 |
| P/B | 1.1 | 1.6 |
| ROE % | -20.3 | -53.3 |
| Net Margin % | -7321.0 | -41.5 |
| Rev Growth 5Y % | -53.8 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
4 محللين
Buy
الحالي
KWD 2.36
المستهدف
KWD 8.25
KWD 7.00
KWD 8.50
KWD 9.00
التوقعات
مكرر الربحية المستقبلي
-2.23
ربحية السهم المستقبلية
-KWD 1.06
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.06
-KWD 1.06 – -KWD 1.06
|
0.0 | 1 |
| FY2026 |
-KWD 0.94
-KWD 0.94 – -KWD 0.94
|
0.0 | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.24
-KWD 0.24 – -KWD 0.24
|
0.0 | 1 |
| 2026 Q1 |
-KWD 0.23
-KWD 0.23 – -KWD 0.23
|
0.0 | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.06 | -KWD 0.31 | -463.6% |
| Q32025 | -KWD 0.04 | -KWD 0.06 | -50.0% |
| Q22025 | -KWD 0.05 | -KWD 0.07 | -50.0% |
| Q12025 | -KWD 0.07 | -KWD 0.04 | +38.5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0.00% | Revenue Growth (3Y) | -59.71% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -53.75% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 632,000.0 | Net Income (TTM) | -46.27 M |
| ROE | -20.31% | ROA | -19.11% |
| Gross Margin | N/A | Operating Margin | -14915.98% |
| Net Margin | -7321.04% | Free Cash Flow (TTM) | N/A |
| ROIC | -32.33% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 14.47 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 216.68 M | Tangible Book Value | 258.92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6.01 | Forward P/E | N/A |
| P/B Ratio | 1.07 | P/S Ratio | 439.64 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | N/A | ||
| Market Cap | 277.85 M | Enterprise Value | 49.79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.21 | Revenue / Share | 0.01 |
| FCF / Share | N/A | OCF / Share | N/A |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1.11% | FCF Conversion | N/A |
| SBC-Adj. FCF | N/A | Growth Momentum | 53.75 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 632,000.0 | 632,000.0 | 3.89 M | -32.12 M | 13.81 M |
| Net Income | -46.27 M | -22.23 M | -206.44 M | -363.53 M | -365.87 M |
| EPS (Diluted) | -0.21 | -0.12 | -1.08 | -1.92 | -2.09 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -94.27 M | -51.43 M | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 62.91 M | 21.77 M | 114.18 M | 131.20 M | 190.34 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | 300,000.0 | 3.40 M | 3.70 M | — |
| Interest Expense | — | — | 102,000.0 | 1,000.0 | 0.0 |
| Income Tax | 0.0 | 0.0 | — | 101,000.0 | -495,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 260.52 M | 212.68 M | 368.03 M | 590.63 M | 878.95 M |
| Total Liabilities | 29.58 M | 11.52 M | 126.03 M | 168.73 M | 163.45 M |
| Shareholders' Equity | 230.94 M | 201.16 M | 242.00 M | 421.90 M | 715.50 M |
| Total Debt | — | — | 4.22 M | 2.75 M | — |
| Cash & Equivalents | 210.63 M | 68.26 M | 301.62 M | 465.99 M | 552.94 M |
| Current Assets | 217.52 M | 176.69 M | 329.11 M | 525.79 M | 750.36 M |
| Current Liabilities | 26.89 M | 8.45 M | 58.00 M | 109.92 M | 97.92 M |
{"event":"ticker_viewed","properties":{"ticker":"NBP","listing_kind":"stock","pathname":"/stocks/nbp","exchange":"Nasdaq","country":"US"}}